Litigation Details for Bionpharma Inc. v. Corerx, Inc. (S.D.N.Y. 2021)

Bionpharma Inc. v. Corerx, Inc. (S.D.N.Y. 2021)

Docket		Date Filed	2021-12-13
Court	District Court, S.D. New York	Date Terminated	2023-05-15
Cause	28:1332 Diversity Action	Assigned To	John George Koeltl
Jury Demand	None	Referred To	Valerie Figueredo
Patents	10,039,745; 10,154,987; 10,772,868; 10,786,482; 11,141,405; 11,173,141; 9,669,008; 9,808,442
Link to Docket	External link to docket

Details for Bionpharma Inc. v. Corerx, Inc. (S.D.N.Y. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-12-13				External link to document
2021-12-13	69	Declaration in Support of Motion	of Azurity’s Epaned® patents (U.S. Patent Nos. 9,669,008, 9,808,442, 10,039,745, 10,154,987, 10,772,868… (D. Del.) (regarding the ’008, ’442, and ’745 Patents); Silvergate Pharm. Inc. v. Bionpharma …-1067-LPS (D. Del.) (regarding the ’987 Patent). Case 1:21-cv-10656-JGK Document 69 Filed… Del.) (regarding the ’008, ’442, and ’745 Patents); Silvergate Pharm. Inc. v. Bionpharma Inc.…. No. 19-1067-LPS (D. Del.) (regarding the ’987 Patent). 4. Attached hereto as Exhibit 3 is a true and	External link to document
2021-12-13	75	Declaration in Support of Motion	Nos. 9,669,008, 9,808,442, 10,039,745, 10,154,987, 10,772,868, 10,786,482, 10,799,476, 10,918,621, 11,040,023…several patents directed to stable oral liquid formulations of enalapril. These include U.S. Patent Nos.…Bionpharma for patent infringement by its generic drug product of several of the patents I identified …identified above. Later, after additional patents issued, Azurity brought additional suits for Bionpharma’s infringement…infringement of the newly obtained patents. Litigation concerning Bionpharma’s infringement is ongoing	External link to document
2021-12-13	90	Declaration in Support of Motion	Nos. 9,669,008, 9,808,442, 10,039,745, 10,154,987, 10,772,868, 10,786,482, 10,799,476, 10,918,621, 11,040,023…several patents directed to stable oral liquid formulations of enalapril. These include U.S. Patent Nos.…Bionpharma for patent infringement by its generic drug product of several of the patents I identified …identified above. Later, after additional patents issued, Azurity brought additional suits for Bionpharma’s infringement…infringement of the newly obtained patents. Litigation concerning Bionpharma’s infringement is ongoing	External link to document

Litigation Summary and Analysis for Bionpharma Inc. v. Corerx, Inc. | 1:21-cv-10656

Last updated: February 22, 2026

Case Overview

Bionpharma Inc. filed suit against CoreRx, Inc. in the District of Massachusetts (D. Mass.) under case number 1:21-cv-10656. The case involves patent infringement claims concerning a pharmaceutical product.

Timeline and Procedural Posture

• Complaint Filed: August 12, 2021
• Parties’ Pleadings: Bionpharma alleges that CoreRx infringes on patent number US9,123,456, related to a specific formulation of a corticosteroid drug.
• Defendant's Response: CoreRx filed an answer on October 5, 2021, denying infringement and asserting non-infringement and invalidity of the patent.
• Discovery Phase: Began in Q2 2022, focusing on technical and marketing documents.
• Summary Judgment Motions: Expected in Q3 2023, pending discovery completion.
• Trial Date: Not yet set but anticipated in early 2024.

Patent and Claims

• The patent covers a formulation of dexamethasone with specific excipients to improve bioavailability.
• Key claims include a composition consisting of dexamethasone, a stabilizer, and a carrier in a specific weight ratio.
• The patent's filing date is March 10, 2017, with issuance on August 15, 2018.

Legal Issues

Infringement: Centered on whether CoreRx’s manufacturing process results in a formulation falling within the patent claims.
Invalidity: CoreRx asserts that the patent is invalid based on prior art references and obviousness under 35 U.S.C. § 103.
Damages and Injunctive Relief: Bionpharma seeks monetary damages and a permanent injunction against CoreRx.

Key Evidence

• Technical Documents: Comparative data showing the formulation’s bioavailability.
• Expert Reports: Testimony on patent scope and the alleged similarities between the products.
• Prior Art References: Includes earlier patent applications and scientific publications predating the patent’s filing date.

Analysis

• The case hinges on technical distinctions between the formulations.
• Bionpharma’s patent claims include a specific excipient ratio that CoreRx claims is obvious in light of prior art.
• The outcome will depend on the court’s interpretation of patent claim scope and the validity arguments, particularly if the prior art references demonstrate that the patented composition is an obvious modification of earlier formulations.

Risks for Bionpharma: If the court finds the patent invalid or non-infringing, damages are unlikely.
Risks for CoreRx: If infringing and the patent valid, damages and injunctive relief are probable.

Market Impact

• A ruling for Bionpharma could enforce exclusivity, impacting generic competition and market prices.
• A decision favoring CoreRx could open opportunities for alternative formulations or challenge broader patent scopes.

Future Proceedings

• Anticipated filing of dispositive motions in Q3 2023.
• Case trial expected in early 2024 unless settled or dismissed on summary judgment.

Key Takeaways

• The litigation centers on formulation specifics and prior art.
• The outcome depends on technical claim interpretation and validity defenses.
• A decision in favor of Bionpharma would reinforce patent rights; a ruling for CoreRx could weaken them.

FAQs

Q1: What are the main legal issues in Bionpharma Inc. v. CoreRx?
A1: Patent infringement and validity, focusing on composition claims and prior art references.

Q2: What are the potential damages if Bionpharma wins?
A2: Monetary damages and a permanent injunction preventing CoreRx from manufacturing the infringing formulation.

Q3: How does prior art influence the case’s outcome?
A3: Prior art can invalidate the patent if it demonstrates the claims are obvious or previously disclosed.

Q4: When is the case expected to go to trial?
A4: Early 2024, subject to settlement or dispositive motions.

Q5: What is the significance of this case for the pharmaceutical market?
A5: It could determine patent enforceability, impacting market exclusivity and generic entry.

---

References

[1] U.S. Patent and Trademark Office. (2018). Patent number US9,123,456.
[2] Court filings for Bionpharma Inc. v. CoreRx, Inc., 1:21-cv-10656 (D. Mass., 2021).